Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Idebenone→

Idebenone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
58186-27-9
Molecular formula
C19H30O5
Molecular weight
338.44 g/mol
Drug class
Synthetic benzoquinonemitochondrial electron-transfer agent and antioxidant
Mechanism of action
A short-chain benzoquinone that can transfer electrons directly to complex III of the mitochondrial electron-transport chain, bypassing defective complex I and supporting cellular ATP generation under conditions of complex I dysfunction. It also has antioxidant activity.
Indications / reported uses
  • Treatment of visual impairment in adolescents and adults with Leber’s hereditary optic neuropathy (LHON), within the authorised product indication.

Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/raxone · https://www.medicines.org.uk/emc/product/2269/smpc · https://www.nice.org.uk/guidance/ta1093 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Idebenone Environmental Risk Assessment (ERA) (the Idebenone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.